Epigenetics Drugs and Diagnostic Technologies Market Research and Forecast 2019-2025

An increase in the aging population, as there is a strong correlation between cancer and aging is the factor that drives the growth of the epigenetics drugs and diagnostic technologies market during the forecast period. As per the WHO, it is expected that population over the age of 60 years that would double from 11% in 2000 to 22% in 2050 and people aged 60 and above are more prone to cancer. Thus, countries are advocating early detection of cancer through screening kits such as Epi ProLung and Epi Procolon that are fuelling the growth of the epigenetics drugs and diagnostic technologies market over the forecast period. Cancer epigenetics is a practical resource for scientists that are engaged in testing, development of epigenetic cancer drugs and discovery.
Epigenetic modifications have considerable implications for translational science as a biomarker for prognosis and diagnosis. Epigenetic modifications are reversible and epigenetic players are found mutated in different cancers, therefore, they provide attractive therapeutic targets.

To learn more about this report request a free sample copy at https://www.omrglobal.com/request-sample/epigenetics-drugs-and-diagnostic-technologies-market

It seems that boomers may want to keep their competitive edge at work and that the widespread use of smartphone cameras may also be a driving factor. The elderly population is more aware and critical of themselves when they take these photos, and that may drive their attention in looking more youthful, which could ultimately drive the global dermatology devices market.

A full report of Global Epigenetics Drugs and Diagnostic Technologies Marketis available at: https://www.omrglobal.com/industry-reports/epigenetics-drugs-and-diagnostic-technologies-market

High prevalence of cancer and other chronic diseases are some of the key factors expected to boost the market. As per the estimation by National Cancer Institute (NIH),the estimated number of cancer deaths in the U.S. is around 163.5 per 100,000 men and women per year. Moreover, the International Cancer Genome Consortium (ICGC) is mainly focused on obtaining epigenomic changes, genomic description and transcriptomic changes in different types of cancers. The Encyclopedia of DNA Elements (ENCODE) project was launched by the US national human genome research institute with the aim to identify all the human genome sequence elements.

The epigenetic mechanisms in the initiation and development of cancers, that they are including DNA methylation, histone modifications, nucleosomes changes, non-coding RNAs. Epigenetic mechanisms are widely involved in human diseases. The reversible nature of epigenetic changes has led to the emergence of novel epigenetic therapeutic approaches. Epigenetics is defined by inherited somatic changes that are not related to changes in the DNA sequence. So, the epigenetic outlook of a cell is determined by the status of DNA methylation, histones covalent modifications, chromatin structure, and non-coding RNAs and networking with each other.

Global Epigenetics Drugs and Diagnostic Technologies Market- Segmentation

By Type

o Histone Deacetylase (HDAC) Inhibitors
o DNA Methyltransferase (DNMT) Inhibitors

By Product

o Reagents
o Kits
o Instruments
o Enzymes
o Services

By Application

o Cancer Disease
o Inflammatory Diseases
o Infectious Diseases
o Cardiovascular Diseases
o Metabolic Diseases
o Other

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/epigenetics-drugs-and-diagnostic-technologies-market

Global Epigenetics Drugs and Diagnostic Technologies Market - Segment by Region

North America

o United States
o Canada

Europe

o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe

Asia-Pacific

o China
o Japan
o India
o Rest of Asia-Pacific

Rest of the World

o Latin America
o Middle East & Africa

Company Profiles

o 4SC AG
o AbbVie, Inc.
o Abcam plc
o Aurobindo Pharma USA, Inc.
o Celgene Corp.
o CellCentric, Ltd.
o Celleron Therapeutics, Ltd.
o Eisai, Inc.
o EpiGentek Group, Inc.
o Epizyme, Inc.
o Illumina, Inc.
o MDxHealth SA
o Merck KGaA
o Novartis AG
o Oncolys BioPharma, Inc.
o Otsuka Pharmaceutical Co., Ltd.
o Promega Corp.
o Syndax Pharmaceuticals, Inc.
o Viracta Therapeutics, Inc.
o Zymo Research Corp.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.